Titan Pharmaceuticals Files Definitive Proxy Statement

Titan Pharmaceuticals Inc DEF 14A Filing Summary
FieldDetail
CompanyTitan Pharmaceuticals Inc
Form TypeDEF 14A
Filed DateMay 2, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, annual-meeting, governance

Related Tickers: TTNP

TL;DR

Titan Pharma (TTNP) proxy filed. Annual meeting June 16. Vote your shares!

AI Summary

Titan Pharmaceuticals, Inc. filed its definitive proxy statement (DEF 14A) on May 2, 2025, for its annual meeting on June 16, 2025. The filing outlines information required for the proxy statement, including details for shareholders to vote on company matters. Titan Pharmaceuticals is in the biological products sector and is incorporated in Delaware.

Why It Matters

This filing is crucial for shareholders as it details the agenda and proposals for the upcoming annual meeting, enabling them to exercise their voting rights on corporate governance and other important company decisions.

Risk Assessment

Risk Level: low — A DEF 14A filing is a routine disclosure document for public companies and does not inherently represent new financial risk.

Key Players & Entities

  • TITAN PHARMACEUTICALS INC (company) — Registrant
  • 0001829126-25-003316 (filing_id) — Accession Number
  • 20250502 (date) — Filing Date
  • 20250616 (date) — Meeting Date
  • 400 OYSTER POINT BLVD SUITE 505 (address) — Company Business Address
  • SAN FRANCISCO, CA 94080 (address) — Company Business Address
  • 6502444990 (phone) — Company Business Phone

FAQ

What is the purpose of this DEF 14A filing?

The purpose of this DEF 14A filing is to provide shareholders with the information required in a proxy statement for the annual meeting of Titan Pharmaceuticals, Inc.

When was this definitive proxy statement filed?

This definitive proxy statement was filed on May 2, 2025.

What is the date of the annual meeting for which this proxy statement is being issued?

The annual meeting for which this proxy statement is being issued is scheduled for June 16, 2025.

What is the company's primary business sector?

The company's primary business sector is Biological Products (No Diagnostic Substances) [2836].

Where is Titan Pharmaceuticals, Inc. incorporated?

Titan Pharmaceuticals, Inc. is incorporated in Delaware (DE).

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on May 2, 2025 regarding TITAN PHARMACEUTICALS INC.

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.